Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 140

1.

Positron lymphography via intracervical 18F-FDG injection for pre-surgical lymphatic mapping in cervical and endometrial malignancies.

Mueller JJ, Dauer LT, Murali R, Iasonos A, Pandit-Taskar N, Abu-Rustum N, Grimm J.

J Nucl Med. 2020 Jan 10. pii: jnumed.119.230714. doi: 10.2967/jnumed.119.230714. [Epub ahead of print]

PMID:
31924717
2.

Characteristics and outcome of AKT1 E17K-mutant breast cancer defined through AACR GENIE, a clinicogenomic registry.

Smyth LM, Zhou Q, Nguyen B, Yu C, Lepisto EM, Arnedos M, Hassett MJ, Lenoue-Newton ML, Blauvelt N, Dogan S, Micheel CM, Wathoo C, Horlings H, Hudecek J, Gross BE, Kundra R, Sweeney SM, Gao J, Schultz N, Zarski A, Gardos SM, Lee J, Sheffler-Collins S, Park BH, Sawyers CL, Andre F, Levy M, Meric-Bernstam F, Bedard PL, Iasonos A, Schrag D, Hyman DM, Genie Consortium AP.

Cancer Discov. 2020 Jan 10. pii: CD-19-1209. doi: 10.1158/2159-8290.CD-19-1209. [Epub ahead of print]

3.

Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway.

Rubinstein MM, Hyman DM, Caird I, Won H, Soldan K, Seier K, Iasonos A, Tew WP, O'Cearbhaill RE, Grisham RN, Hensley ML, Troso-Sandoval T, Sabbatini P, Guillen J, Selcuklu SD, Zimel C, Torrisi J, Aghajanian C, Makker V.

Cancer. 2019 Dec 27. doi: 10.1002/cncr.32677. [Epub ahead of print]

PMID:
31880826
4.

Ethical and Policy Issues for Seamless Phase I Oncology Trials.

Hutchinson N, Vinarov E, Iasonos A, Kimmelman J.

J Clin Oncol. 2019 Dec 26:JCO1902456. doi: 10.1200/JCO.19.02456. [Epub ahead of print] No abstract available.

PMID:
31877086
5.

TRK Fusions are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations.

Rosen EY, Goldman DA, Hechtman JF, Benayed R, Schram AM, Cocco E, Shifman S, Gong Y, Kundra R, Solomon JP, Bardelli A, Scaltriti M, Drilon A, Iasonos A, Taylor BS, Hyman DM.

Clin Cancer Res. 2019 Dec 23. pii: clincanres.3165.2019. doi: 10.1158/1078-0432.CCR-19-3165. [Epub ahead of print]

6.

Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery.

Liu YL, Filippova OT, Zhou Q, Iasonos A, Chi DS, Zivanovic O, Sonoda Y, Gardner GJ, Broach VA, O'Cearbhaill RE, Konner JA, Aghajanian C, Long Roche K, Tew WP.

J Gynecol Oncol. 2020 Jan;31(1):e17. doi: 10.3802/jgo.2020.31.e17.

7.

Patient-reported outcomes after surgery for endometrial carcinoma: Prevalence of lower-extremity lymphedema after sentinel lymph node mapping versus lymphadenectomy.

Leitao MM Jr, Zhou QC, Gomez-Hidalgo NR, Iasonos A, Baser R, Mezzancello M, Chang K, Ward J, Chi DS, Long Roche K, Sonoda Y, Brown CL, Mueller JJ, Gardner GJ, Jewell EL, Broach V, Zivanovic O, Dowdy SC, Mariani A, Abu-Rustum NR.

Gynecol Oncol. 2019 Nov 25. pii: S0090-8258(19)31624-5. doi: 10.1016/j.ygyno.2019.11.003. [Epub ahead of print]

PMID:
31780238
8.

Coherence principles in interval-based dose finding.

Wages NA, Iasonos A, O'Quigley J, Conaway MR.

Pharm Stat. 2019 Nov 6. doi: 10.1002/pst.1974. [Epub ahead of print]

PMID:
31692233
9.

Subsequent therapies and survival after immunotherapy in recurrent ovarian cancer.

Liu YL, Zhou Q, Iasonos A, Emengo VN, Friedman C, Konner JA, O'Cearbhaill RE, Aghajanian C, Zamarin D.

Gynecol Oncol. 2019 Oct;155(1):51-57. doi: 10.1016/j.ygyno.2019.08.006. Epub 2019 Aug 14.

PMID:
31421916
10.

A descriptive report of outcomes of primary mucinous ovarian cancer patients receiving either an adjuvant gynecologic or gastrointestinal chemotherapy regimen.

Schlappe BA, Zhou QC, O'Cearbhaill R, Iasonos A, Soslow RA, Abu-Rustum NR, Mueller JJ.

Int J Gynecol Cancer. 2019 May 15. pii: ijgc-2018-000150. doi: 10.1136/ijgc-2018-000150. [Epub ahead of print]

PMID:
31097512
11.

Efficacy of MEK inhibition in patients with histiocytic neoplasms.

Diamond EL, Durham BH, Ulaner GA, Drill E, Buthorn J, Ki M, Bitner L, Cho H, Young RJ, Francis JH, Rampal R, Lacouture M, Brody LA, Ozkaya N, Dogan A, Rosen N, Iasonos A, Abdel-Wahab O, Hyman DM.

Nature. 2019 Mar;567(7749):521-524. doi: 10.1038/s41586-019-1012-y. Epub 2019 Mar 13.

12.

Use, Safety, and Efficacy of Single-Patient Use of the US Food and Drug Administration Expanded Access Program.

Feit NZ, Goldman DA, Smith E, Deighan J, Iasonos A, Zivanovic O, Hyman DM.

JAMA Oncol. 2019 Apr 1;5(4):570-572. doi: 10.1001/jamaoncol.2018.7002. No abstract available.

13.

Variance prior specification for a basket trial design using Bayesian hierarchical modeling.

Cunanan KM, Iasonos A, Shen R, Gönen M.

Clin Trials. 2019 Apr;16(2):142-153. doi: 10.1177/1740774518812779. Epub 2018 Dec 7.

PMID:
30526008
14.

Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade.

Boland JL, Zhou Q, Martin M, Callahan MK, Konner J, O'Cearbhaill RE, Friedman CF, Tew W, Makker V, Grisham RN, Hensley ML, Zecca N, Iasonos AE, Snyder A, Hyman DM, Sabbatini P, Aghajanian C, Cadoo KA, Zamarin D.

Gynecol Oncol. 2019 Feb;152(2):251-258. doi: 10.1016/j.ygyno.2018.11.025. Epub 2018 Nov 22.

15.

Perioperative epidural use and survival outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer.

Tseng JH, Cowan RA, Afonso AM, Zhou Q, Iasonos A, Ali N, Thompson E, Sonoda Y, O'Cearbhaill RE, Chi DS, Abu-Rustum NR, Long Roche K.

Gynecol Oncol. 2018 Nov;151(2):287-293. doi: 10.1016/j.ygyno.2018.08.024. Epub 2018 Sep 2.

16.

Continuous improvement in primary Debulking surgery for advanced ovarian cancer: Do increased complete gross resection rates independently lead to increased progression-free and overall survival?

Tseng JH, Cowan RA, Zhou Q, Iasonos A, Byrne M, Polcino T, Polen-De C, Gardner GJ, Sonoda Y, Zivanovic O, Abu-Rustum NR, Long Roche K, Chi DS.

Gynecol Oncol. 2018 Oct;151(1):24-31. doi: 10.1016/j.ygyno.2018.08.014. Epub 2018 Aug 17.

17.

A Randomized Trial of Prophylactic Extended Carboplatin Infusion to Reduce Hypersensitivity Reactions in Recurrent Ovarian Cancer.

LaVigne K, Hyman DM, Zhou QC, Iasonos A, Tew WP, Aghajanian C, Makker V, Hensley ML, Konner J, Grisham RN, Cangemi N, Soldan K, Spriggs DR, Sabbatini PJ, OʼCearbhaill RE.

Int J Gynecol Cancer. 2018 Jul;28(6):1176-1182. doi: 10.1097/IGC.0000000000001280.

18.

Adjuvant chemotherapy in patients with operable granulosa cell tumors of the ovary: a surveillance, epidemiology, and end results cohort study.

Oseledchyk A, Gennarelli RL, Leitao MM Jr, Aghajanian CA, Iasonos A, Zivanovic O, Zamarin D.

Cancer Med. 2018 Jun;7(6):2280-2287. doi: 10.1002/cam4.1447. Epub 2018 Apr 17.

19.

Exploring the impact of income and race on survival for women with advanced ovarian cancer undergoing primary debulking surgery at a high-volume center.

Cowan RA, Tseng J, Ali N, Dearie H, Murthy V, Gennarelli RL, Iasonos A, Abu-Rustum NR, Chi DS, Long Roche KC, Brown CL.

Gynecol Oncol. 2018 Apr;149(1):43-48. doi: 10.1016/j.ygyno.2017.11.012.

20.

International Study of Primary Mucinous Ovarian Carcinomas Managed at Tertiary Medical Centers.

Mueller JJ, Lajer H, Mosgaard BJ, Bach Hamba S, Morice P, Gouy S, Hussein Y, Soslow RA, Schlappe BA, Zhou QC, Iasonos A, Høgdall C, Leary A, O'Cearbhaill RE, Abu-Rustum NR.

Int J Gynecol Cancer. 2018 Jun;28(5):915-924. doi: 10.1097/IGC.0000000000001263.

21.

Report of the 14th International Conference on Malignant Lymphoma (ICML) Closed Workshop on Future Design of Clinical Trials in Lymphomas.

Stathis A, Iasonos A, Seymour JF, Thieblemont C, Ribrag V, Zucca E, Younes A.

Clin Cancer Res. 2018 Jul 1;24(13):2993-2998. doi: 10.1158/1078-0432.CCR-17-3021. Epub 2018 Mar 13.

22.

Prospective Comparative Study of Laparoscopic Narrow Band Imaging (NBI) Versus Standard Imaging in Gynecologic Oncology.

Aloisi A, Sonoda Y, Gardner GJ, Park KJ, Elliott SL, Zhou QC, Iasonos A, Abu-Rustum NR.

Ann Surg Oncol. 2018 Apr;25(4):984-990. doi: 10.1245/s10434-017-6314-4. Epub 2018 Jan 16.

23.

Phase I Designs that Allow for Uncertainty in the Attribution of Adverse Events.

Iasonos A, O'Quigley J.

J R Stat Soc Ser C Appl Stat. 2017 Nov;66(5):1015-1030. doi: 10.1111/rssc.12195. Epub 2016 Nov 7.

24.

Time to publication of oncology trials and why some trials are never published.

Chapman PB, Liu NJ, Zhou Q, Iasonos A, Hanley S, Bosl GJ, Spriggs DR.

PLoS One. 2017 Sep 21;12(9):e0184025. doi: 10.1371/journal.pone.0184025. eCollection 2017.

25.

Surgical site infection reduction bundle in patients with gynecologic cancer undergoing colon surgery.

Schiavone MB, Moukarzel L, Leong K, Zhou QC, Afonso AM, Iasonos A, Roche KL, Leitao MM Jr, Chi DS, Abu-Rustum NR, Zivanovic O.

Gynecol Oncol. 2017 Oct;147(1):115-119. doi: 10.1016/j.ygyno.2017.07.010. Epub 2017 Jul 19.

26.

A reconstructed melanoma data set for evaluating differential treatment benefit according to biomarker subgroups.

Satagopan JM, Iasonos A, Kanik JG.

Data Brief. 2017 May 5;12:667-675. doi: 10.1016/j.dib.2017.05.005. eCollection 2017 Jun.

27.

Clinical Trials in the Genomic Era.

Joffe E, Iasonos A, Younes A.

J Clin Oncol. 2017 Mar 20;35(9):1011-1017. doi: 10.1200/JCO.2016.70.8891. Epub 2017 Feb 13. Review.

28.

A comparative analysis of prediction models for complete gross resection in secondary cytoreductive surgery for ovarian cancer.

Cowan RA, Eriksson AGZ, Jaber SM, Zhou Q, Iasonos A, Zivanovic O, Leitao MM Jr, Abu-Rustum NR, Chi DS, Gardner GJ.

Gynecol Oncol. 2017 May;145(2):230-235. doi: 10.1016/j.ygyno.2017.02.010. Epub 2017 Mar 9.

PMID:
28285846
29.

A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel.

Smyth LM, Monson KR, Jhaveri K, Drilon A, Li BT, Abida W, Iyer G, Gerecitano JF, Gounder M, Harding JJ, Voss MH, Makker V, Ho AL, Razavi P, Iasonos A, Bialer P, Lacouture ME, Teitcher JB, Erinjeri JP, Katabi N, Fury MG, Hyman DM.

Invest New Drugs. 2017 Dec;35(6):742-750. doi: 10.1007/s10637-017-0445-0. Epub 2017 Mar 9.

30.

Survival of Patients with Serous Uterine Carcinoma Undergoing Sentinel Lymph Node Mapping.

Schiavone MB, Scelzo C, Straight C, Zhou Q, Alektiar KM, Makker V, Soslow RA, Iasonos A, Leitao MM, Abu-Rustum NR.

Ann Surg Oncol. 2017 Jul;24(7):1965-1971. doi: 10.1245/s10434-017-5816-4. Epub 2017 Mar 3.

31.

Measuring differential treatment benefit across marker specific subgroups: The choice of outcome scale.

Satagopan JM, Iasonos A.

Contemp Clin Trials. 2017 Dec;63:40-50. doi: 10.1016/j.cct.2017.02.007. Epub 2017 Feb 22.

32.

A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer.

Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Iyer RB, Zhou Q, Iasonos A, Denesopolis J, Zivanovic O, Long Roche KC, Sonoda Y, Coleman RL, Abu-Rustum NR, Hricak H, Chi DS.

Gynecol Oncol. 2017 Apr;145(1):27-31. doi: 10.1016/j.ygyno.2017.02.020. Epub 2017 Feb 14.

33.

An efficient basket trial design.

Cunanan KM, Iasonos A, Shen R, Begg CB, Gönen M.

Stat Med. 2017 May 10;36(10):1568-1579. doi: 10.1002/sim.7227. Epub 2017 Jan 18.

34.

Picking the Right Patient for Human Epidermal Growth Factor Receptor 3-Targeted Therapy in Platinum-Resistant Ovarian Cancer.

Schram AM, Iasonos A, Hyman DM.

J Clin Oncol. 2016 Dec 20;34(36):4312-4314. Epub 2016 Oct 23. No abstract available.

35.

Early phase dose finding methodology.

Iasonos A, O'Quigley J.

Stat Med. 2017 Jan 30;36(2):201-203. doi: 10.1002/sim.7155. No abstract available.

PMID:
27921353
36.

Basket Trials in Oncology: A Trade-Off Between Complexity and Efficiency.

Cunanan KM, Gonen M, Shen R, Hyman DM, Riely GJ, Begg CB, Iasonos A.

J Clin Oncol. 2017 Jan 20;35(3):271-273. doi: 10.1200/JCO.2016.69.9751. Epub 2016 Nov 28. Review. No abstract available.

37.

Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center.

Mueller JJ, Kelly A, Zhou Q, Iasonos A, Long Roche K, Sonoda Y, O'Cearbhaill RE, Zivanovic O, Chi DS, Gardner GJ.

Gynecol Oncol. 2016 Dec;143(3):496-503. doi: 10.1016/j.ygyno.2016.09.014. Epub 2016 Sep 28.

38.

Dose expansion cohorts in Phase I trials.

Iasonos A, O'Quigley J.

Stat Biopharm Res. 2016;8(2):161-170. Epub 2016 Jun 2.

39.

Integrating the escalation and dose expansion studies into a unified Phase I clinical trial.

Iasonos A, O'Quigley J.

Contemp Clin Trials. 2016 Sep;50:124-34. doi: 10.1016/j.cct.2016.06.010. Epub 2016 Jul 5.

40.

Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive Biomarker.

Iasonos A, Chapman PB, Satagopan JM.

Clin Cancer Res. 2016 May 1;22(9):2114-20. doi: 10.1158/1078-0432.CCR-15-2517. Review.

41.

A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission.

O'Cearbhaill RE, Ragupathi G, Zhu J, Wan Q, Mironov S, Yang G, Spassova MK, Iasonos A, Kravetz S, Ouerfelli O, Spriggs DR, Danishefsky SJ, Sabbatini PJ.

Cancers (Basel). 2016 Apr 22;8(4). pii: E46. doi: 10.3390/cancers8040046.

42.

Dimension of model parameter space and operating characteristics in adaptive dose-finding studies.

Iasonos A, Wages NA, Conaway MR, Cheung K, Yuan Y, O'Quigley J.

Stat Med. 2016 Sep 20;35(21):3760-75. doi: 10.1002/sim.6966. Epub 2016 Apr 18.

43.

Measuring Toxicity in Phase I Clinical Trials--Letter.

Hyman DM, Eaton A, Ivy SP, Spriggs DR, Iasonos A.

Clin Cancer Res. 2016 Apr 1;22(7):1828. doi: 10.1158/1078-0432.CCR-15-3043. No abstract available.

44.

Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program.

Drilon A, Eaton AA, Schindler K, Gounder MM, Spriggs DR, Harris P, Ivy SP, Iasonos A, Lacouture ME, Hyman DM.

Cancer. 2016 Apr 15;122(8):1228-37. doi: 10.1002/cncr.29918. Epub 2016 Feb 24.

45.

Sequential monitoring of Phase I dose expansion cohorts.

Iasonos A, O'Quigley J.

Stat Med. 2017 Jan 30;36(2):204-214. doi: 10.1002/sim.6894. Epub 2016 Feb 7.

46.

An Assessment of Prognostic Factors, Adjuvant Treatment, and Outcomes of Stage IA Polyp-Limited Versus Endometrium-Limited Type II Endometrial Carcinoma.

Liang LW, Perez AR, Cangemi NA, Zhou Q, Iasonos A, Abu-Rustum N, Alektiar KM, Makker V.

Int J Gynecol Cancer. 2016 Mar;26(3):497-504. doi: 10.1097/IGC.0000000000000635.

47.

Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center.

Mueller JJ, Zhou QC, Iasonos A, O'Cearbhaill RE, Alvi FA, El Haraki A, Eriksson AG, Gardner GJ, Sonoda Y, Levine DA, Aghajanian C, Chi DS, Abu-Rustum NR, Zivanovic O.

Gynecol Oncol. 2016 Mar;140(3):436-42. doi: 10.1016/j.ygyno.2016.01.008. Epub 2016 Jan 9.

48.

Reply to M.P. Decatris et al.

Hyman DM, Solit DB, Iasonos A.

J Clin Oncol. 2016 Mar 10;34(8):887. doi: 10.1200/JCO.2015.65.2487. Epub 2016 Jan 11. No abstract available.

PMID:
26755514
49.

A Phase 2, Single Arm Study of Iniparib in Patients With BRCA1 or BRCA2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

Bell-McGuinn KM, Konner JA, Tew WP, Hensley ML, Iasonos A, Charpentier E, Mironov S, Sabbatini P, Aghajanian C.

Int J Gynecol Cancer. 2016 Feb;26(2):255-60. doi: 10.1097/IGC.0000000000000591.

50.

Clinical trials: Early phase clinical trials-are dose expansion cohorts needed?

Iasonos A, O'Quigley J.

Nat Rev Clin Oncol. 2015 Nov;12(11):626-8. doi: 10.1038/nrclinonc.2015.174. Epub 2015 Oct 6. No abstract available.

Supplemental Content

Loading ...
Support Center